Garrison, M.W., Schimmels, J.A. and Madaras-Kelly, K.J. (2003) In Vitro Pharmacodynamic Activity of Gatifloxacin, Gemifloxacin, Moxifloxacin and Levofloxacin against Streptococcus pneumoniae Containing Specific Mutations in DNA Gyrase and Topoisomerase IV. Diagnostic Microbiology and Infectious Disease, 47, 587-593.
https://doi.org/10.1016/S0732-8893(03)00152-4

has been cited by the following article:

• TITLE: Antimicrobial Effects of Gatifloxacin on Canine Periodontopathic Bacteria In Vitro

  AUTHORS: Tadashi Miura, Yukari Oda, Koji Tanabe, Yasuhiko Shizawa, Taichi Ito, Longqiang Yang

  KEYWORDS: Periodontal Disease, Antibiotics, Dog, Porphyromonas gulae, Veterinary Medicine

  JOURNAL NAME: Journal of Biomedical Science and Engineering, Vol.15 No.2, February 21, 2022

  ABSTRACT: The aim of this study was to identify the potential antibacterial effects of gatifloxacin on one of canine periodontal pathogens, Porphyromonas gulae. The minimum inhibitory concentrations (MIC) of gatifloxacin and its bactericidal effects were investigated. Gatifloxacin inhibited the growth of the canine periodontopathic bacteria tested in broth. An MIC of 50 nM was found to be effective in inhibiting P. gulae. On performing adenosine triphosphate bioluminescence assay, gatifloxacin was found to exhibit bactericidal effects on the tested bacteria in a concentration-dependent manner. The safety of gatifloxacin in mammalian cells was evaluated by assessing the viability of rat bone marrow mesenchymal stem (BMMS) cells treated with gatifloxacin. Almost over 80% of BMMS cells survived after a 3-day culture when treated with 100 nM of gatifloxacin. These results indicate that locally administered gatifloxacin has the potential for being used to prevent canine periodontal infection.